Valuation dashboard for Grifols, S.A. (GRFS) with P/E 16.42, P/B 1.35, EV/EBITDA 8.3 and dividend yield 0.75%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions.
What would it be worth at its usual multiples?
Versus its usual multiples: fairly priced · Current P/E 16.4× · Multiples range: $8.31 · $15.91.
At the decade median (16.0×) $8 (-2 %); at its sector median (30.7×) $16 (+87 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Analysis Summary
Grifols, S.A. reported revenue of 7.23B EUR in the most recent fiscal year, growing at a 5-year CAGR of 6.2%. Net income reached 386.1M EUR, with a -9.0% 5-year CAGR.
Trailing-twelve-month margins: gross margin 37.2%, operating margin 16.7%, net margin 6.1%.
At $8.51 (closing price, November 2, 2026), GRFS trades at a P/E of 16.42 and an ROE of 8.43%. Market capitalisation stands at $7.2B.
Balance sheet quality for GRFS: debt-to-equity ratio of 1.54, current ratio of 2.37 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 16.42 |
| Price / Book | 1.35 |
| EV / EBITDA | 8.3 |
| Dividend Yield | 0.75% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GRFS | Grifols, S.A. | $7.2B | 16.42 | 1.35 | 8.4% |
| TECH | Bio-Techne Corporation | $11.4B | 62.65 | 5.38 | 8.9% |
| ADMA | ADMA Biologics, Inc. | $2.5B | 15.80 | 6.18 | 39.6% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.0B | 5.20 | -35.4% | |
| ABT | Abbott Laboratories | $190.6B | 40.80 | 3.75 | 9.1% |
| BDX | Becton, Dickinson and Company | $54.1B | 59.82 | 2.24 | 3.8% |
| BIO | Bio-Rad Laboratories, Inc. | $9.8B | 44.38 | 1.39 | 3.2% |
| HAE | Haemonetics Corporation | $5.5B | 58.89 | 6.51 | 11.3% |
Price
| Price | $8.51 (closing price, November 2, 2026) |
| Market Cap | $7.2B |
| Exchange | NASDAQ |
| Country | ES |
Profitability
| Return on Equity | 8.43% |
| Return on Invested Capital | 5.47% |
| Return on Assets | 2.25% |
| Gross Margin | 37.23% |
| Operating Margin | 16.66% |
| Net Margin | 6.09% |
Related companies: TECH · ADMA · MRVI · ABT · BDX · BIO · HAE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of GRFS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks